Qatar Investment Authority (QIA) has participated in a $132 million Series B investment round for US-based Artbio, a biotech company pioneering targeted alpha radiotherapy (ARTs) for cancer treatment.
This marks QIA’s first investment in Artbio, which is developing a next-generation class of targeted alpha radiotherapies to treat a diverse range of cancers.
The round was co-led by Sofinnova Investments and B Capital, alongside a life sciences fund that previously backed Artbio, and saw participation from existing investors including F-Prime, Omega Funds, and Third Rock Ventures. Alexandria Venture Investments also joined as a new investor.
Artbio stated that the funding will support the advancement of its innovative clinical-stage targeted radiotherapies, aiming to redefine cancer treatment approaches.
This investment aligns with QIA’s ongoing strategy to grow its footprint in the biotech and therapeutic sectors. Earlier this month, QIA committed $250 million to Karidum, an innovative healthcare company, reinforcing its focus on cutting-edge therapeutic technologies. QIA currently manages over $524 billion in assets globally.
